Scarica l'app Stockscreener
108.27
0.46%
-0.50
Pre-mercato:
107.88
-0.39
-0.36%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$108.77
Aprire:
$108.01
Volume 24 ore:
16.59M
Relative Volume:
2.26
Capitalizzazione di mercato:
$188.27B
Reddito:
$44.33B
Utile/perdita netta:
$6.48B
Rapporto P/E:
29.24
EPS:
3.7033
Flusso di cassa netto:
$6.92B
1 W Prestazione:
-10.62%
1M Prestazione:
-13.27%
6M Prestazione:
-14.44%
1 anno Prestazione:
-16.35%
Intervallo 1D:
$106.96
$109.35
Intervallo di 1 settimana:
$105.78
$122.49
Portata 52W:
$105.78
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Nome
Abbott Laboratories
Settore
Industria
Telefono
(224) 667-6100
Indirizzo
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Confronta ABT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
108.27 | 189.14B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
BSX
Boston Scientific Corp
|
93.61 | 138.74B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
354.57 | 136.52B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.69 | 129.06B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.60 | 48.90B | 5.88B | 1.34B | 799.60M | 2.3489 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-10 | Iniziato | The Benchmark Company | Buy |
| 2025-07-18 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-06-16 | Iniziato | Leerink Partners | Market Perform |
| 2024-10-08 | Iniziato | Oppenheimer | Outperform |
| 2024-09-19 | Iniziato | Piper Sandler | Overweight |
| 2024-07-30 | Downgrade | Edward Jones | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2023-07-21 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Reiterato | Barclays | Overweight |
| 2023-04-20 | Reiterato | Bernstein | Outperform |
| 2023-04-20 | Reiterato | JP Morgan | Overweight |
| 2023-04-20 | Reiterato | Raymond James | Outperform |
| 2023-04-20 | Reiterato | UBS | Buy |
| 2023-04-20 | Reiterato | Wolfe Research | Underperform |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2022-10-26 | Iniziato | Mizuho | Neutral |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-06 | Iniziato | Wolfe Research | Underperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-01-27 | Reiterato | Credit Suisse | Outperform |
| 2022-01-27 | Reiterato | Morgan Stanley | Overweight |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | UBS | Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-10-27 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Iniziato | Redburn | Neutral |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-01-28 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Outperform |
| 2020-06-01 | Downgrade | Goldman | Neutral → Sell |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-06-13 | Reiterato | BofA/Merrill | Buy |
| 2019-02-07 | Reiterato | BofA/Merrill | Buy |
| 2019-01-02 | Downgrade | Citigroup | Neutral → Sell |
| 2018-11-30 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-10-16 | Iniziato | Barclays | Overweight |
| 2018-06-27 | Iniziato | Bernstein | Outperform |
| 2018-01-30 | Reiterato | Citigroup | Neutral |
| 2018-01-25 | Reiterato | Stifel | Buy |
| 2018-01-25 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Iniziato | Evercore ISI | Outperform |
| 2018-01-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-19 | Reiterato | Stifel | Buy |
Mostra tutto
Abbott Laboratories Borsa (ABT) Ultime notizie
Abbott Laboratories Stock Now 19% Cheaper, Time To Buy - Trefis
What To Expect From Stryker’s (SYK) Q4 Earnings - TradingView
Is Abbott (ABT) Insider Buying Offsetting Concerns Around Nutrition and Diagnostics Earnings Pressure? - simplywall.st
Abbott Laboratories (NYSE:ABT) Finds Support After Recent S&P 500 Decline - Kalkine Media
Abbott: Study shows neuromod systems greatly reduce pain-related healthcare visits - MassDevice
Abbott executive who led TAVR, Tendyne divisions announces exit - Cardiovascular Business
Transcatheter Embolization and Occlusion Devices Market Size to be Valued at USD 11.53 Billion by 2033, Driven by Rising Oncology and Neurovascular Interventions – SNS Insider - GlobeNewswire Inc.
Lbp Am Sa Boosts Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Optimism around Abbott Laboratories (NYSE:ABT) delivering new earnings growth may be shrinking as stock declines 11% this past week - Yahoo Finance
ABT.SW Abbott Laboratories (SIX) CHF100 27 Jan 2026 volume spike: watch momentum - Meyka
Top Executive Makes Bold Move With Major Abbott Laboratories Stock Purchase - TipRanks
Abbott Reworks Nutrition While Targeting Cancer Diagnostics With Exact Sciences Deal - simplywall.st
Ill. Judge Trims False Ad Suit Over Abbott Formula - Law360
Evercore ISI says Abbott’s (ABT) core growth drivers are still intact - MSN
Abbott Laboratories (ABT) Rebounds After Recent Losses - GuruFocus
Abbott Laboratories snaps six straight sessions of losses - MSN
Evercore ISI Says Abbott’s (ABT) Core Growth Drivers Are Still Intact - Insider Monkey
Hedge Fund and Insider Trading News: Ken Griffin, Bill Ackman, Mala Gaonkar, Millennium Management, Berkshire Hathaway, Abbott Laboratories (ABT), GameStop Corp (GME), and More - Insider Monkey
Abbott Eterna Spinal Cord Stimulator Lawsuit Filed Over Lead Migration, Device Malfunction - AboutLawsuits.com
AtaCor Medical Teams Up with Abbott on Defibrillator - ocbj.com
Abbott Laboratories (ABT) CEO Increases Stake with $2M Stock Pur - GuruFocus
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Ford Robert B, Abbott Laboratories chairman, buys $2 million in ABT - Investing.com Nigeria
Ford Robert B buys Abbott shares worth $2m By Investing.com - Investing.com Nigeria
Mutual of America Capital Management LLC Sells 10,889 Shares of Abbott Laboratories $ABT - MarketBeat
3 Reasons to Buy This Dividend King After Its Steep Sell-Off - The Motley Fool
Abbott TAVR leader Chris Waddell is leaving the company - MassDevice
Abbott’s Pōkeno Entry Signals Strategic Nutrition Play - en.edairynews.com
Abbott Laboratories stock faces a Monday test as ABT hovers near a 52-week low - TechStock²
A Look At Abbott Laboratories (ABT) Valuation After Recent Share Price Weakness - simplywall.st
Abbott Laboratories: Double-Digit Earnings Growth Makes It A Buy (NYSE:ABT) - Seeking Alpha
Sawgrass Asset Management LLC Trims Stake in Abbott Laboratories $ABT - MarketBeat
Commerzbank Aktiengesellschaft FI Buys 20,825 Shares of Abbott Laboratories $ABT - MarketBeat
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Maravai Lifesciences Holdings (MRVI) and CVRx (CVRX) - The Globe and Mail
Is Abbott's January pullback a good time to buy? - MSN
Is Abbott’s January Pullback a Good Time to Buy? - MarketBeat
Mn Services Vermogensbeheer B.V. Acquires 9,900 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Sold by Resona Asset Management Co. Ltd. - MarketBeat
Abbott Laboratories $ABT Shares Purchased by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
UniSuper Management Pty Ltd Buys 44,239 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Sold by Gibbs Wealth Management - MarketBeat
Abbott Laboratories: The Market's Overreaction Is The Long-Term Investor's Opportunity - Seeking Alpha
Abbott Laboratories (ABT) Margin Compression Challenges Steady Compounder Narrative After FY 2025 Results - simplywall.st
Abbott Laboratories Analyst Cuts Price Target After Q4 Miss, Expects Sales Growth To Accelerate In H2 - Sahm
Earnings snapshot: Abbott Laboratories Q4 beats profit estimates, but misses on revenue; initiates Q1 and FY26 outlook - MSN
Abbott Laboratories (NYSE:ABT) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Assessing Abbott Laboratories (ABT) Valuation After Q4 2025 Earnings Miss And Softer 2026 Guidance - Yahoo Finance
Citigroup Cuts Abbott Laboratories (NYSE:ABT) Price Target to $140.00 - MarketBeat
Key facts: Abbott Laboratories' stock drops 10.21%; CEO seeks changes; brokers optimistic - TradingView
Abbott India Under Scrutiny Due To Cough Syrup Supply ChainAbbott Laboratories (NYSE:ABT) - Benzinga
Tesla To $360? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
Abbott Laboratories Azioni (ABT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.06%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):